Analysis of results to optimize anticoagulant therapy in patients who underwent mechanical heart valve replacement: a pilot singlecenter controlled study

Aim. This study aims to conduct a comparative analysis of anticoagulant-related complications and clinical outcomes in patients with mechanical aortic valve prostheses who are on long-term warfarin therapy. The analysis will focus on two groups: those maintained at therapeutic INR values (3 ± 0.5) and those maintained at reduced INR values (2 ± 0.5). Material and methods. The analysis of a prospective, randomized, single-center study included 80 patients (56% men and 44% women) who underwent mechanical aortic valve replacement between March 2020 and September 2022. The observation period lasted 12 months, with an average age of 59 years (range: 50-63). The primary endpoint was a composite outcome measured over 12 months, consisting of death, symptomatic bleeding, thrombosis, and thromboembolism. Patients were enrolled based on the following inclusion criteria: mechanical prosthesis in the aortic position implanted more than three months prior, age over 18 at the time of inclusion, and provision of written informed consent. Exclusion criteria included multivalvular prosthetics, history of cardiac cavity thrombosis, left ventricular ejection fraction of less than 30%, atrial fibrillation/flutter, pregnancy or plans for pregnancy during the study, patient refusal at any stage of the study, liver pathology (types B and C according to Child- Pugh), and severe renal failure (creatinine clearance <30 ml/ min). Results. All participants (n = 80, 100%) completed the pilot study. Among the 40 patients in the study group, 6 (7.5%) experienced events related to the primary endpoint. The odds ratio for the primary endpoint at 12 months was 2.71 (p = 0.25). Additionally, the odds ratio for the primary endpoint at 18 months was calculated to be 3.35 (p = 0.155). Given the observed negative trend in the frequency of disabling events in the primary group, and despite the lack of statistically significant differences, the study was terminated at the pilot stage for ethical reasons. Conclusion. This study reveals a negative trend in the frequency of primary endpoint events among patients with reduced INR levels. Notably, the majority of these events consisted of ischemic strokes, which occurred in 5% of the study group. Consequently, the optimal target INR range for patients who have undergone heart valve replacement with mechanical prostheses remains inadequately defined

1. Aluru JS, Barsouk A, Saginala K, Rawla P, Barsouk A. Valvular Heart Disease Epidemiology. Med Sci (Basel). 2022;10(2):32. https://doi.org/10.3390/medsci10020032

2. Bazylev VV, Mikulyak AI, Shmatkov MG, Senzhapov IYa, Denisov MA. Open mitral valve replacement with a balloon-expandable prosthesis using the valve-in-valve technique: a case report. Patologiya krovoobrashcheniya i kardiokhirurgiya = Circulation Pathology and Cardiac Surgery. 2024;28(1):19–25. (In Russ.). https://doi.org/10.21688/1681-3472-2024-1-19-25

3. Komarov RN, Noginov VK. The possibilities of valve-sparing surgical treatment of bicuspid aortic valve syndrome. Patologiya krovoobrashcheniya i kardiokhirurgiya = Circulation Pathology and Cardiac Surgery. 2022;26(2):9–16. (In Russ.). https://doi.org/10.21688/1681-3472-2022-2-9-16

4. Yesiltas MA, Haberal İ, Kuserli Y, Yildiz A, Koyuncu AO, Özsoy SD. Comparison of Short and Mid-Term Mortality and Morbidity in Patients with Severe Aortic Stenosis (Intermediate/High Risk) Who Underwent Transcatheter Aortic Valve Replacement and Surgical Aortic Valve Replacement. Heart Surg Forum. 2020;23(2):E212– E220. https://doi.org/10.1532/hsf.2913

5. Johansson I, Benz AP, Kovalova T, Balasubramanian K, Fukakusa B, Lynn MJ et al. Outcomes of Patients with a Mechanical Heart Valve and Poor Anticoagulation Control on Warfarin. Thromb. Haemost. 2024;124(7):613–624. https://doi.org/10.1055/s-0043-1777827

6. Williams MA, van Riet S. The On-X heart valve: mid-term results in a poorly anticoagulated population. J Heart Valve Dis. 2006;15:80–86. https://doi.org/10.1111/j.0886-0440.2004.04084.x

7. Taniguchi S, Hashizume K, Ariyoshi T, Hisata Y, Tanigawa K, Miura T,et al. Twelve years of experience with the ATS mechanical heart valve prostheses. Gen Thorac Cardiovasc Surg. 2012;60(9):561–568. https://doi.org/10.1007/s11748-012-0124-1

8. Gerdisch MW, Hagberg RC, Perchinsky MJ, Joseph M, Oo AY, Loubani M et al. Low-dose warfarin with a novel mechanical aortic valve: Interim registry results at 5-year follow-up. J Thorac Cardiovasc Surg. 2024;168(6):1645–1655.e6. https://doi.org/10.1016/j.jtcvs.2024.04.017

9. Puskas JD, Gerdisch M, Nichols D, Fermin L, Rhenman B, Kapoor D et al. PROACT Investigators. Anticoagulation and Antiplatelet Strategies After On-X Mechanical Aortic Valve Replacement. J Am Coll Cardiol. 2018;71(24):2717–2726. https://doi.org/10.1016/j.jacc.2018.03.535

10. Enginoev ST, Ziankou AA, Chernov II, Dzhambieva MN, Ramazanova NE, Baev DYu et al. Immediate and mid-term results of implanting a MedInzh-2 mechanical prosthesis in the aortic position: ten-year experience of one center. Creative surgery and oncology. 2024;14(1):20–28. (In Russ.). https://doi.org/10.24060/2076-3093-2024-14-1-20-28

11. Trella M., Torella D., Chiodini P., Franciulli M., Romano G., De Santo L. et al. LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the "LOWERING-IT" Trial. Am. Heart J. 2010;160(1):171–178. https://doi.org/10.1016/j.ahj.2010.05.005